Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 217

1.

Eukaryotic Translation Initiation Factor 4A Down-Regulation Mediates Interleukin-24-Induced Apoptosis through Inhibition of Translation.

Zhong X, Persaud L, Muharam H, Francis A, Das D, Aktas BH, Sauane M.

Cancers (Basel). 2018 May 22;10(5). pii: E153. doi: 10.3390/cancers10050153.

PMID:
29786657
2.

RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients.

Keup C, Mach P, Aktas B, Tewes M, Kolberg HC, Hauch S, Sprenger-Haussels M, Kimmig R, Kasimir-Bauer S.

Clin Chem. 2018 May 16. pii: clinchem.2017.283531. doi: 10.1373/clinchem.2017.283531. [Epub ahead of print]

PMID:
29769179
3.

Low serum melatonin levels are associated with erectile dysfunction.

Bozkurt A, Karabakan M, Aktas BK, Gunay M, Keskin E, Hirik E.

Int Braz J Urol. 2018 Apr 30;44. doi: 10.1590/S1677-5538.IBJU.2017.0663. [Epub ahead of print]

PMID:
29757573
4.

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.

Banys-Paluchowski M, Fehm T, Janni W, Aktas B, Fasching PA, Kasimir-Bauer S, Milde-Langosch K, Pantel K, Rack B, Riethdorf S, Solomayer EF, Witzel I, Müller V.

BMC Cancer. 2018 May 8;18(1):541. doi: 10.1186/s12885-018-4282-0.

5.

Identification of di-substituted ureas that prevent growth of trypanosomes through inhibition of translation initiation.

Machado FC, Franco CH, Dos Santos Neto JV, Dias-Teixeira KL, Moraes CB, Lopes UG, Aktas BH, Schenkman S.

Sci Rep. 2018 Mar 20;8(1):4857. doi: 10.1038/s41598-018-23259-9.

6.

Successful Treatment of Amyloid A-Type Amyloidosis Due to Behçet Disease With Tocilizumab.

Ilbay A, Erden A, Sari A, Armagan B, Aktas BY, Bolek EC, Kalyoncu U, Karadag O.

J Clin Rheumatol. 2018 Feb 22. doi: 10.1097/RHU.0000000000000724. [Epub ahead of print] No abstract available.

PMID:
29470263
7.

The eIF2α Kinase Heme-Regulated Inhibitor Protects the Host from Infection by Regulating Intracellular Pathogen Trafficking.

Bahnan W, Boucher JC, Gayle P, Shrestha N, Rosen M, Aktas B, Adkins B, Ager A, Khan WN, Schesser K.

Infect Immun. 2018 Feb 20;86(3). pii: e00707-17. doi: 10.1128/IAI.00707-17. Print 2018 Mar.

PMID:
29311243
8.

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer.

Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V.

Sci Rep. 2017 Dec 11;7(1):17307. doi: 10.1038/s41598-017-17514-8.

9.

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.

Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, von Schumann R, Kates R, Kates R, Schumacher J, Wuerstlein R, Kreipe HH, Harbeck N.

J Natl Cancer Inst. 2017 Dec 8. doi: 10.1093/jnci/djx258. [Epub ahead of print]

PMID:
29228315
10.

Emerging Role for the PERK/eIF2α/ATF4 in Human Cutaneous Leishmaniasis.

Dias-Teixeira KL, Calegari-Silva TC, Medina JM, Vivarini ÁC, Cavalcanti Á, Teteo N, Santana AKM, Real F, Gomes CM, Pereira RMS, Fasel N, Silva JS, Aktas BH, Lopes UG.

Sci Rep. 2017 Dec 6;7(1):17074. doi: 10.1038/s41598-017-17252-x.

11.

Comparison of 18F-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study.

Sawicki LM, Kirchner J, Grueneisen J, Ruhlmann V, Aktas B, Schaarschmidt BM, Forsting M, Herrmann K, Antoch G, Umutlu L.

Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):622-629. doi: 10.1007/s00259-017-3881-3. Epub 2017 Nov 21.

PMID:
29164299
12.

Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer.

Kaya S, Aktas B, Tanrikulu Sismek E, Akif Ozturk M, Dede F, Kaya H, Ugurlu U, Ozgen Z, Koca S, Halil S, Hasanov R, Alan O, Akgul Babacan N, Ercelep O, Dane F, Gumus M, Yumuk F.

J BUON. 2017 Sep-Oct;22(5):1191-1198.

PMID:
29135102
13.

The eIF2-alpha kinase HRI: a potential target beyond the red blood cell.

Burwick N, Aktas BH.

Expert Opin Ther Targets. 2017 Dec;21(12):1171-1177. doi: 10.1080/14728222.2017.1397133. Epub 2017 Oct 30. Review.

14.

Comparison of 18F-FDG PET/MRI and MRI for pre-therapeutic tumor staging of patients with primary cancer of the uterine cervix.

Sarabhai T, Schaarschmidt BM, Wetter A, Kirchner J, Aktas B, Forsting M, Ruhlmann V, Herrmann K, Umutlu L, Grueneisen J.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):67-76. doi: 10.1007/s00259-017-3809-y. Epub 2017 Aug 24.

PMID:
28840302
15.

Dry needling in lateral epicondylitis: a prospective controlled study.

Uygur E, Aktaş B, Özkut A, Erinç S, Yilmazoglu EG.

Int Orthop. 2017 Nov;41(11):2321-2325. doi: 10.1007/s00264-017-3604-1. Epub 2017 Aug 21.

PMID:
28828509
16.

Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer.

Bredemeier M, Edimiris P, Mach P, Kubista M, Sjöback R, Rohlova E, Kolostova K, Hauch S, Aktas B, Tewes M, Kimmig R, Kasimir-Bauer S.

Clin Chem. 2017 Oct;63(10):1585-1593. doi: 10.1373/clinchem.2016.269605. Epub 2017 Aug 3.

PMID:
28778937
17.

A rare case of a medullary, multifocal lesion in the distal radius.

Aktas B, Ozturan B, Kilic B, Demiroglu M, Ozkan K.

JRSM Open. 2017 Jul 6;8(7):2054270417710396. doi: 10.1177/2054270417710396. eCollection 2017 Jul.

18.

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.

Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA.

J Clin Oncol. 2017 Sep 10;35(26):3046-3054. doi: 10.1200/JCO.2016.71.9815. Epub 2017 Jul 6.

PMID:
28682681
19.

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N.

Breast Cancer Res Treat. 2017 Oct;165(3):573-583. doi: 10.1007/s10549-017-4358-6. Epub 2017 Jun 29.

PMID:
28664507
20.

Early ovarian cancer surgery with indocyanine-green-guided targeted compartmental lymphadenectomy (TCL, pelvic part).

Kimmig R, Buderath P, Rusch P, Mach P, Aktas B.

J Gynecol Oncol. 2017 Sep;28(5):e68. doi: 10.3802/jgo.2017.28.e68. Epub 2017 Jun 13.

21.

Development of 1-((1,4-trans)-4-Aryloxycyclohexyl)-3-arylurea Activators of Heme-Regulated Inhibitor as Selective Activators of the Eukaryotic Initiation Factor 2 Alpha (eIF2α) Phosphorylation Arm of the Integrated Endoplasmic Reticulum Stress Response.

Yefidoff-Freedman R, Fan J, Yan L, Zhang Q, Dos Santos GRR, Rana S, Contreras JI, Sahoo R, Wan D, Young J, Dias Teixeira KL, Morisseau C, Halperin J, Hammock B, Natarajan A, Wang P, Chorev M, Aktas BH.

J Med Chem. 2017 Jul 13;60(13):5392-5406. doi: 10.1021/acs.jmedchem.7b00059. Epub 2017 Jun 19.

PMID:
28590739
22.

Impact of Exopolysaccharides (EPSs) of Lactobacillus gasseri strains isolated from human vagina on cervical tumor cells (HeLa).

Sungur T, Aslim B, Karaaslan C, Aktas B.

Anaerobe. 2017 Oct;47:137-144. doi: 10.1016/j.anaerobe.2017.05.013. Epub 2017 May 26.

PMID:
28554813
23.

Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.

Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V.

Anticancer Res. 2017 Jun;37(6):3117-3128.

PMID:
28551653
24.
25.

eIF2α Phosphorylation Mediates IL24-Induced Apoptosis through Inhibition of Translation.

Persaud L, Zhong X, Alvarado G, Do W, Dejoie J, Zybtseva A, Aktas BH, Sauane M.

Mol Cancer Res. 2017 Aug;15(8):1117-1124. doi: 10.1158/1541-7786.MCR-16-0454. Epub 2017 May 1.

26.
27.

Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.

Bredemeier M, Kasimir-Bauer S, Kolberg HC, Herold T, Synoracki S, Hauch S, Edimiris P, Bankfalvi A, Tewes M, Kimmig R, Aktas B.

Mol Med Rep. 2017 May;15(5):2957-2968. doi: 10.3892/mmr.2017.6415. Epub 2017 Mar 30.

28.

Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69).

Furlanetto J, Jackisch C, Untch M, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Wiebringhaus H, Kümmel S, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Costa SD, Gerber B, Nekljudova V, Loibl S, von Minckwitz G.

Breast Cancer Res Treat. 2017 Jun;163(3):495-506. doi: 10.1007/s10549-017-4200-1. Epub 2017 Mar 17.

PMID:
28315068
29.

A Case of Schwannoma of the Common Peroneal Nerve in the Knee.

Öz TT, Aktaş B, Özkan K, Özturan B, Kilic B, Demiroğlu M.

Orthop Rev (Pavia). 2017 Feb 21;9(1):6825. doi: 10.4081/or.2017.6825. eCollection 2017 Feb 20.

30.

Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients.

Grueneisen J, Sawicki LM, Wetter A, Kirchner J, Kinner S, Aktas B, Forsting M, Ruhlmann V, Umutlu L.

Eur J Radiol. 2017 Apr;89:14-19. doi: 10.1016/j.ejrad.2016.12.019. Epub 2017 Jan 22.

PMID:
28267530
31.

Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT.

Kirchner J, Sawicki LM, Suntharalingam S, Grueneisen J, Ruhlmann V, Aktas B, Deuschl C, Herrmann K, Antoch G, Forsting M, Umutlu L.

PLoS One. 2017 Feb 22;12(2):e0172553. doi: 10.1371/journal.pone.0172553. eCollection 2017.

32.

Aortic utero-ovarian sentinel nodes and left infrarenal aortic lymph node dissection by ICG supported navigation.

Kimmig R, Rusch P, Buderath P, Aktas B.

Gynecol Oncol Rep. 2017 Feb 9;20:22-23. doi: 10.1016/j.gore.2017.02.003. eCollection 2017 May.

33.

Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer.

Kolberg HC, Aktas B, Liedtke C.

Rev Recent Clin Trials. 2017;12(2):67-72. doi: 10.2174/1574887112666170201143321.

PMID:
28155606
34.

Surgical anatomy of the ligamentous mesometrium and robotically assisted ICG-guided resection in cervical cancer.

Kimmig R, Buderath P, Rusch P, Aktas B.

Gynecol Oncol Rep. 2017 Jan 21;20:4. doi: 10.1016/j.gore.2017.01.008. eCollection 2017 May.

35.

Effect of age on biochemical recurrence after radical prostatectomy.

Ozden C, Aktas BK, Bulut S, Erbay G, Tagci S, Gokkaya CS, Baykam MM, Memis A.

Kaohsiung J Med Sci. 2017 Feb;33(2):91-95. doi: 10.1016/j.kjms.2016.11.002. Epub 2016 Dec 23.

36.

Evaluation of a novel ELISA for the tumor-associated antigen CA 72-4 in patients with ovarian cancer.

Buderath P, Kasimir-Bauer S, Aktas B, Rasch J, Kimmig R, Zeller T, Heubner M.

Future Sci OA. 2016 Oct 12;2(4):FSO145. doi: 10.4155/fsoa-2016-0040. eCollection 2016 Dec.

37.

Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years.

Kolberg HC, Akpolat-Basci L, Stephanou M, Aktas B, Hannig CV, Liedtke C.

Breast Care (Basel). 2016 Oct;11(5):323-327. Epub 2016 Oct 24.

38.

Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.

Wali VB, Langdon CG, Held MA, Platt JT, Patwardhan GA, Safonov A, Aktas B, Pusztai L, Stern DF, Hatzis C.

Cancer Res. 2017 Jan 15;77(2):566-578. doi: 10.1158/0008-5472.CAN-16-1901. Epub 2016 Nov 21.

39.

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.

Loibl S, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Wiebringhaus H, Kümmel S, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Dan Costa S, Gerber B, Engels K, Nekljudova V, von Minckwitz G, Untch M; investigators of the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) study groups.

Ann Oncol. 2017 Mar 1;28(3):497-504. doi: 10.1093/annonc/mdw610.

PMID:
27831502
40.

The Role of M30 in Predicting the Severity of Liver Fibrosis and Inflammation in Chronic Hepatitis B Patients.

Yilmaz B, Aktas B, Altinbas A, Ginis Z, Ozturk G, Ekiz F, Kilincalp S, Deveci M, Simsek Z, Coban S, Basar O, Yuksel O.

Hepat Mon. 2016 Aug 10;16(9):e35640. eCollection 2016 Sep.

41.

Note: 3D printed spheroid for uniform magnetic field generation.

Öztürk Y, Aktaş B.

Rev Sci Instrum. 2016 Oct;87(10):106103.

PMID:
27802690
42.

Left paraaortic, inframesenteric lymphadenectomy preserving the superior hypogastric plexus supported by indocyanine green (ICG) labeling of the lymphatic compartment in cervical cancer.

Kimmig R, Rusch P, Buderath P, Aktas B.

Gynecol Oncol Rep. 2016 Sep 14;18:14. doi: 10.1016/j.gore.2016.09.002. eCollection 2016 Nov.

43.

Unveiling the Role of the Integrated Endoplasmic Reticulum Stress Response in Leishmania Infection - Future Perspectives.

Dias-Teixeira KL, Pereira RM, Silva JS, Fasel N, Aktas BH, Lopes UG.

Front Immunol. 2016 Jul 22;7:283. doi: 10.3389/fimmu.2016.00283. eCollection 2016.

44.

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.

Aktas B, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, Pantel K, Tewes M; DETECT Study Group.

BMC Cancer. 2016 Jul 25;16:522. doi: 10.1186/s12885-016-2587-4.

45.

Comparing the type and severity of inflammatory bowel disease in relation to IgG4 immunohistochemical staining.

Şimşek HD, Basyigit S, Aktas B, Vargol E, Şimşek GG, Küçükazman M, Nazlıgül Y.

Acta Gastroenterol Belg. 2016 Apr-Jun;79(2):216-21.

PMID:
27382941
46.

Robotically assisted peritoneal mesometrial resection (PMMR) in endometrial cancer supported by ICG labeling of the compartmental lymphatic system.

Kimmig R, Aktas B, Buderath P, Heubner M.

Gynecol Oncol Rep. 2016 Mar 19;16:24. doi: 10.1016/j.gore.2016.03.004. eCollection 2016 Apr.

47.

The Impact of Lactobacillus casei on the Composition of the Cecal Microbiota and Innate Immune System Is Strain Specific.

Aktas B, De Wolfe TJ, Safdar N, Darien BJ, Steele JL.

PLoS One. 2016 May 31;11(5):e0156374. doi: 10.1371/journal.pone.0156374. eCollection 2016.

48.

Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment.

Bredemeier M, Edimiris P, Tewes M, Mach P, Aktas B, Schellbach D, Wagner J, Kimmig R, Kasimir-Bauer S.

Oncotarget. 2016 Jul 5;7(27):41677-41690. doi: 10.18632/oncotarget.9528.

49.

Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?

Kasimir-Bauer S, Reiter K, Aktas B, Bittner AK, Weber S, Keller T, Kimmig R, Hoffmann O.

Sci Rep. 2016 May 23;6:26355. doi: 10.1038/srep26355.

50.

WILKIE'S SYNDROME: A RARE CAUSE OF INTESTINAL OBSTRUCTION.

Kefeli A, Aktürk A, Aktaş B, Çalar K.

Arq Bras Cir Dig. 2016 Mar;29(1):68. doi: 10.1590/0102-6720201600010020. English, Portuguese. No abstract available.

Supplemental Content

Support Center